Michael J. Wagner

Michael Wagner practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Michael Wagner's NPI, 1023317898, was assigned on March 19, 2011. Michael Wagner graduated from Harvard Medical School in 2011. Michael Wagner holds Massachusetts license 1016422.

Michael Wagner's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Michael Wagner's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Michael Wagner is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Binney Medical Group. Dmand AI also links Michael Wagner to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Michael Wagner practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Michael Wagner's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Michael Wagner is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Michael Wagner's licenses on file in 2 states: Massachusetts and Washington.

CMS data shows 215 Medicare services from Michael Wagner across 5 procedure codes in 2024, for 106 Medicare patients. Medicare paid $23,769 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 106 Medicare patients who saw Michael Wagner in 2024. The largest group is 65 to 74, with 52 patients. 72% of them have high blood pressure, and 67% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Michael Wagner's median patient age at 67, with 58% women.

In 2024, Michael Wagner wrote 70 Medicare Part D claims for 27 patients. 99% of them were for generic drugs. They cover 3 drugs, with $56,279 in total drug cost. In 2022, CMS named 124 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Michael Wagner for performance year 2024, reported as part of a group. Michael Wagner accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Michael Wagner as offering telehealth.

Dmand AI links 1 paper to Michael Wagner in 2023. Michael Wagner's most frequent co-authors are Robert Brown, MD, Robert Stephen Brown, MD and Brett Emerson Fortune, MD.

CMS Open Payments shows 25 general payments to Michael Wagner from 9 drug and device companies from 2016 to 2025. Grants make up the largest share, 82% of the total. Millennium Pharmaceuticals, Inc. paid the most, $66,667. It also lists 4 research payments totaling $1,119 in 2019.

Michael Wagner graduated from Harvard Medical School in 2011.